Pfizer combo therapy boosts survival in bladder cancer trial , Pg II

Key Highlights:

• Pfizer's cancer drug Padcev, combined with Merck's Keytruda, significantly improved survival in patients with muscle-invasive bladder cancer.
• The combination therapy showed significant improvement in event-free survival and overall survival compared to surgery alone.
• Pfizer plans to discuss trial results with global health authorities for potential regulatory filings.

Detailed Insights:

• Muscle-invasive bladder cancer is when cancer has spread into the muscle layer of the bladder wall, requiring aggressive treatment.
• The late-stage trial evaluated the combination therapy's effectiveness in preventing disease recurrence and extending life expectancy.
• Event-free survival is a critical measure in cancer treatment, indicating the duration a patient remains cancer-free after therapy.
• Regulatory filings with global health authorities are the next step to potentially make this combination therapy available to patients.

Key Concepts Involved:

• Combination Therapy: The use of two or more drugs to treat a disease, often to improve effectiveness.
• Clinical Trial: A research study to evaluate the safety and efficacy of new medical treatments or interventions.